NYSE:LCI (USA) Also Trade In: Germany

Lannett Co Inc $ 6.70 -0.16 (-2.33%)

On watch
Avg Vol (1m):
Market Cap $:
279.39 Mil
Enterprise Value $:
849.77 Mil
P/E (TTM):
Warning! GuruFocus has detected 8 Severe warning signs with LCI. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

LCI News and Headlines - Lannett Co Inc

GuruFocus Articles Total 15
  • 1

Down big over the last three years, but still profitable, Lannett is worth a flyer

For over 75 years, Lannett Co. Inc. (LCI) has been turning branded pharmaceutical products into their generic versions. Currently, it sells a broad range of drugs that address virtually any therapeutic need.

Generally, drug manufacturers are fairly reliant on fleeting patents and heavy capital spending that too often push market caps far above the underlying company's intrinsic value. Thus, the public stocks attached to these companies should rarely be considered as long-term investments. But, with Lannett, comparing its current fundamentals to the market, industry and the company's own five-year average, makes the stock looks like a no brainer -- at

120 Views    Jonathan Poland    2018-10-19 16:13
Pharmaceutical company recently lost major supplier

Snow Capital Management leader Richard Snow (Trades, Portfolio) disclosed this week that he reduced his Lannett Co. Inc. (LCI) position by 84.76% on Aug. 21.

The guru’s Milwaukee-based firm takes a contrarian, relative value approach to stock picking, typically investing in financially strong companies that are experiencing a temporary setback.

According to GuruFocus real-time picks, Snow sold 2.04 million shares of Lannett for an average price of $5.70 per share, impacting the portfolio by -0.53%. He now holds 367,208 shares, which represents 0.1% of his equity portfolio.


GuruFocus data shows

174 Views    Sydnee Gatewood    2018-09-13 16:52
Guru trims ON Semiconductor, exits Dynagas, Energy Transfer Partners

Ronald Muhlenkamp (TradesPortfolio), founder of Muhlenkamp & Company, sold shares of the following stocks during the fourth quarter.

The guru reduced his ON Semiconductor Corp. (ON) stake by 16.39%, impacting the portfolio by -1.16%.


The company, which manufactures semiconductor components, has a market cap of $10.39 billion and an enterprise value of $12.42 million.

GuruFocus gives the company a profitability and growth rating of 8 out of 10. Its return on equity (ROE) of 37.23% and return on assets (ROA) of 11.77% are outperforming 83% of companies in the Global Semiconductors

88 Views    Tiziano Frateschi    2018-03-06 20:12
The largest insider buys of Macquarie, OPKO, New Residential Investment, Lannett and DeVry

According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below:

Macquarie Infrastructure CEO bought 15,000 shares

Macquarie Infrastructure Corp. (MIC) CEO James Hooke bought 15,000 shares on Feb. 3 for $74.15 per share. The stock price has increased by 8% since.

Macquarie owns, operates and invests in groups of infrastructure businesses including bulk liquid terminals, International-Matex Tank Terminals, airport services, Atlantic Aviation and Hawaii Gas. Macquarie has a market cap of $6.55 billion. As of Feb. 10 its shares

231 Views    Joy Hu    2017-02-13 17:55
Insider invests in 10,000 shares

Lannett Co. Inc. (LCI) CEO Arthur Bedrosian purchased 10,000 shares of the company for $20 per share on Feb. 6, according to a Form 4 filing with the Securities and Exchange Commission. He now owns 688,909 shares of the company.

Lannett has a market cap of $761.27 million, an enterprise value of $1.55 billion, a price-book (P/B) ratio of 1.46 and a price-sales (P/S) ratio of 1.20.

Headquartered in Philadelphia, Lannett engages in the development, manufacture, market and distribution of generic pharmaceutical products. The company was founded in 1942, and its pharmaceutical products are distributed to drug

226 Views    Kyle Ferguson    2017-02-08 22:18
Company's protease inhibitors are equivalent to AbbVie's Kaletra oral solution

Lannet Co. Inc. (LCI) announced through the PRNewswire Tuesday that its “Lopinavir and Ritonavir Oral Solution USP, 80 mg/20 mg per mL” has been approved by the U.S. Food and Drug Administration (FDA) to be produced and sold in the U.S. as a generic drug.

Lannett’s protease inhibitors, a class of antiretroviral drugs for the treatment of HIV positive patients and patients with AIDS, are equivalent to AbbVie’s (ABBV) Kaletra oral solution.

Combinations of protease inhibitor drugs are administered to HIV positive people if the basic treatment made up of a cocktail of antiretroviral drugs, which is usually composed

204 Views    Alberto Abaterusso    2017-01-05 23:12
Teva Pharmaceutical shares lost half their value in 2016


We like Teva for three reasons. First, despite being in the generic segment where it is difficult to gain a competitive advantage, we believe that Teva has an advantage over its competitors, namely because of its size. Second, the company is growing. Unfortunately, most of this growth is coming from M&A activity. EPS has been $1.49 in 2013, $3.56 in 2014 and $1.82 in 2015 (5.46 non-GAAP).

Third, despite its growth and good fundamentals, the stock price has plummeted. This year it has lost 45%. It is now trading close to its 52-week low. Is there something wrong with

1093 Views    Cristiano Bellavitis, Ph.D.    2017-01-02 22:58
Akorn is a strong pharmaceutical company that trades at conservative prices


Akorn is a specialty generic pharmaceutical company. We like Akorn for multiple reasons. First, despite being in the generic segment, it focuses on products that are more difficult to manufacture compared to other drugs. Therefore, Akorn manufacturing capabilities insulates the company from low price competition.

Second, the company is rapidly growing and is executing its strategy very efficiently.


From 2010 to 2015, Akorn traded at a P/E multiple ranging from 27.1 in 2011 to 95.3 in 2014, for an average P/E of 46 (source: 4-Traders). It now trades at 13.4X 2016 earnings and 12.4X 2017 earnings. We

715 Views    Cristiano Bellavitis, Ph.D.    2017-01-02 02:26
An overview of the guru's largest trades of the 3rd quarter

Richard Snow (Trades, Portfolio) is the founder of Snow Capital. Snow began his career investing the proceeds from the sale of the Snow family businesses. The guru’s largest third quarter trades are the following:

The guru boosted his stake in Kinder Morgan Inc. (KMI) by 16,330.30%. The trade had an impact of 2.52% on the portfolio.

The company, through its subsidiaries, owns and operates pipelines that transport natural gas, gasoline, crude oil, carbon dioxide and other products. Third quarter net loss available to common stockholders was $227 million, compared to net income available to common stockholders of

1220 Views    Tiziano Frateschi    2016-11-16 21:55
Value guru Richard Snow likes long-term opportunities with short-term downturns and loves oil

In his first-quarter portfolio, released Wednesday, Richard Snow (Trades, Portfolio) reported buying 12 new stocks from diverse industries during the period.

Snow is president and CEO of Snow Capital Management, a contrarian, relative value-investing firm that takes advantage of price declines in stocks of companies encountering temporary negative events from which they will likely recover. It has $4.6 billion in assets under management.

In Snow Capital Management's Snow Capital Family of Funds annual letter to shareholders from February, managers wrote:Â

"Now, we believe the value style

1633 Views    Holly LaFon    2016-05-12 20:16
Generic drug manufacturer is mispriced due to irrational fears

I use several different techniques to search for potential investment opportunities. But, there is no question that I strongly favor value investing because I like large margins of safety surrounding my money.

Another thing I do is closely follow businesses to which I have allocated capital, especially when the price falls 19% in about three months. In such a case, there exists a strong possibility that I missed something important in my original assessment.

There is also a reasonable possibility that it is simply another case of the market having mispriced a stock. In these cases, I want to determine

4692 Views    Ken McGaha    2016-01-12 20:43
Lannett's stock has increased 12% since December with more upside potential

It seems to be a fairly constant theme in my articles that I like cheap businesses that provide essential products and services to their customers.

Today, I feel compelled to try one more time to point one out what represents one of the most compelling values in the market today. I published an analysis on this business at the end of December last year. It only attracted 457 page views.

I hope everyone who read the piece bought the stock. As of last Friday’s close, it is up 12.05% since the article was published on GuruFocus. This is an exceptional

3195 Views    Ken McGaha    2015-10-13 21:28
Fund trailed the small-cap benchmark, returning just 0.1% year-to-date


Royce 100 Fund was down 0.1% for the year-to-date period ended June 30, 2015, trailing its smallcap benchmark, the Russell 2000 Index, which gained 4.8% for the same period.

The Fund’s difficulties began with the new year—it uncharacteristically lost more than its benchmark during the bearish January. As the first quarter moved on and share prices began to recover, the Fund was unable to keep pace with the small-cap index in large part because of the more growthoriented nature of small-cap leadership. For the first quarter 100 Fund was up 0.5% compared to a 4.3% gain for

1725 Views    Cody Eustice    2015-09-20 22:12

For the month of March, the following stocks are considered must-buys by the research staff at Zacks Investment Research.

End-to-end process of drug making

One pharmaceutical company that has witnessed amazing growth rates recently and is all set to reach great heights in the future is Sucampo Pharmaceuticals (SCMP). What sets this company apart from the rest is that Sucampo deals with the end-to-end process of drug making. This involves analysis, research, testing, developing and marketing the drug. The two drugs that have made the company a well-known brand are Amitiza and Rescula. Other than these, Sucampo is involved in

519 Views    reports.droy    2015-03-04 19:38
  • Lannett Company provides products its customers require.
  • By its very nature, it provides them at a lower price than many competitors.
  • The business is priced at a low earnings multiple for its industry and the actual valuation is even better.
  • Aging populations and rising incomes around the world virtually assure future growth.

Driven by the irreversible trends of an aging population and the rising healthcare spending that comes with it, businesses that can provide products that treat our maladies and help reduce the cost of care will inevitably prosper. With its currently low valuation, improving earnings projection and

519 Views    Ken McGaha    2014-12-29 15:25

Headlines Total 60
  • 1

2020-11-24 $ 6.39 (3.9%)
2020-11-05 $ 6.97 (0.43%)
2020-10-28 $ 6.39 (-4.2%)
2020-09-04 $ 5.41 (1.12%)
2020-08-31 $ 5.26 (0.96%)
2020-08-27 $ 5.16 (-14.71%)
2020-07-16 $ 5.96 (15.95%)
2020-06-03 $ 7.47 (-0.27%)
2020-05-07 $ 7.58 (-20.04%)
2020-04-27 $ 9.22 (1.21%)
2020-04-02 $ 6.63 (3.11%)
2019-10-05 $ 11.97 (2.05%)
2019-08-15 $ 6.48 (-4.28%)
2019-05-17 $ 5.92 (2.96%)
2019-05-07 $ 7.68 (-15.42%)
2018-10-26 $ 3.47 (-1.14%)
2018-10-24 $ 3.43 (-7.05%)
2018-10-23 $ 3.71 (-4.13%)
2018-10-22 $ 3.71 (-4.13%)
2018-10-20 $ 3.87 (%)
2018-10-19 $ 3.87 (%)
2018-10-16 $ 4.16 (3.74%)
2018-10-11 $ 3.91 (0.77%)
2018-10-10 $ 3.88 (4.58%)
2018-10-09 $ 3.75 (-20.55%)
2018-10-06 $ 4.72 (-4.07%)
2018-09-28 $ 4.75 (-1.04%)
2018-09-22 $ 5 (-9.09%)
2018-09-20 $ 5.5 (13.4%)
2018-09-15 $ 5.15 (-0.96%)
2018-09-14 $ 5.2 (0.97%)
2018-09-13 $ 5.2 (0.97%)
2018-09-08 $ 5.65 (3.67%)
2018-09-06 $ 5.4 (-2.7%)
2018-08-31 $ 5.35 (%)
2018-08-29 $ 5.35 (-3.6%)
2018-08-27 $ 5.1 (-0.97%)
2017-02-08 $ 21.05 (2.18%)
2016-01-12 $ 35.68 (1.45%)
2015-10-13 $ 44.45 (-4.1%)
2014-12-29 $ 42.99 (2.04%)
2010-11-12 $ 5.5 (-2.14%)
2010-09-24 $ 4.35 (4.32%)
2010-05-13 $ 4.83 (-3.78%)
2010-02-11 $ 4.19 (-7.3%)
2009-11-12 $ 6.27 (-3.98%)
2009-09-28 $ 8.2 (0.74%)
2009-05-13 $ 5.89 (3.33%)
2009-02-11 $ 5 (1.83%)
Total 60
  • 1